HC Wainwright & Co. Reiterates Buy on Iovance Biotherapeutics, Maintains $38 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and maintains $38 price target.
American Express, Visa And Other Big Stocks Moving Higher In Friday’s Pre-Market Session
U.S. stock futures traded slightly lower this morning. Here are some big stocks recording gains in today’s pre-market trading session.
Piper Sandler Upgrades Iovance Biotherapeutics to Overweight, Raises Price Target to $14
Piper Sandler analyst Joseph Catanzaro upgrades Iovance Biotherapeutics (NASDAQ:IOVA) from Neutral to Overweight and raises the price target from $11 to $14.
The Latest Analyst Ratings for Iovance Biotherapeutics
Iovance Biotherapeutics (NASDAQ:IOVA) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…
Iovance Biotherapeutics Acquires Clinigen’s IL-2 Product For Upfront £166.7M
Iovance Biotherapeutics Inc (NASDAQ:IOVA) has agreed to acquire worldwide rights to Proleukin (aldesleukin), an interleukin-2 (IL-2) product, from Clinigen Limited. Iovance expects…
What 6 Analyst Ratings Have To Say About Iovance Biotherapeutics
Within the last quarter, Iovance Biotherapeutics (NASDAQ:IOVA) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…
Goldman Sachs Downgrades Iovance Biotherapeutics to Neutral, Lowers Price Target to $6
Goldman Sachs analyst Madhu Kumar downgrades Iovance Biotherapeutics (NASDAQ:IOVA) from Buy to Neutral and lowers the price target from $20 to $6.
12 Health Care Stocks Moving In Monday’s Intraday Session
Gainers Nymox Pharmaceutical (NASDAQ:NYMX) shares increased by 32.7% to $0.38 during Monday’s regular session. As of 12:30 EST,…
Iovance Biotherapeutics Pushes FDA Rolling Submission Deadline Into Next Year For Its Lead Skin Cancer Candidate
Iovance Biotherapeutics Inc (NASDAQ:IOVA) announced that its ongoing rolling Biologics License Application (BLA) submission to the FDA for lifileucel…
Earnings Scheduled For November 3, 2022
Companies Reporting Before The Bell
• Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion.